{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:56:24Z","timestamp":1792716984495,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T00:00:00Z","timestamp":1448496000000},"content-version":"vor","delay-in-days":329,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1038\/jid.2014.306","type":"journal-article","created":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T09:48:15Z","timestamp":1405936095000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":334,"title":["Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic\/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study"],"prefix":"10.1016","volume":"135","author":[{"given":"Sarbjit S.","family":"Saini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bindslev-Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"B\u00fclb\u00fcl Baskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Canvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelkader","family":"Rahmaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oral","family":"Alpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheldon","family":"Spector","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Ros\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/jid.2014.306_bb0010","first-page":"34","article-title":"Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses","volume":"32","author":"Asero","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1038\/jid.2014.306_bb0015","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fc\u03b5RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.306_bb0020","author":"European Medicines Agency"},{"key":"10.1038\/jid.2014.306_bb0025","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1038\/jid.2014.306_bb0030","author":"Genentech, Inc. and Novartis Pharmaceuticals Corporation"},{"issue":"suppl 1","key":"10.1038\/jid.2014.306_bb0035","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.jaci.2007.12.1121","article-title":"Effect of anti-IgE (omalizumab) in chronic idiopathic urticaria (CIU) patients (abstract)","volume":"121","author":"Gober","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.306_bb0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2013.05.013","article-title":"Omalizumab in patients with symptomatic chronic idiopathic\/spontaneous urticaria despite standard combination therapy","volume":"132","author":"Kaplan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.306_bb0045","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2008.07.006","article-title":"Treatment of chronic autoimmune urticaria with omalizumab","volume":"122","author":"Kaplan","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.306_bb0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.anai.2010.06.011","article-title":"Development of a daily diary for patients with chronic idiopathic urticaria","volume":"105","author":"Mathias","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1038\/jid.2014.306_bb0055","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.306_bb0060","first-page":"971","article-title":"Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria","volume":"11","author":"Maurer","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1038\/jid.2014.306_bb0065","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1038\/jid.2014.306_bb0070","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jaci.2005.05.035","article-title":"Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge","volume":"116","author":"Ong","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.306_bb0075","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","article-title":"A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine\u2013refractory chronic idiopathic urticaria","volume":"128","author":"Saini","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.306_bb0080","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0952-7915(02)00404-1","article-title":"How IgE upregulates the allergic response","volume":"14","author":"Saini","year":"2002","journal-title":"Curr Opin Immunol"},{"key":"10.1038\/jid.2014.306_bb0085","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2009.11.047","article-title":"The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria","volume":"125","author":"Staevska","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1038\/jid.2014.306_bb0090","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/14740338.2011.563840","article-title":"Safety of omalizumab in asthma","volume":"10","author":"Tan","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1038\/jid.2014.306_bb0095","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.coi.2008.09.005","article-title":"New concepts in chronic urticaria","volume":"20","author":"Vonakis","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1038\/jid.2014.306_bb0100","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1398-9995.2009.02179.x","article-title":"EAACI\/GA2LEN\/EDF\/WAO guideline: definition, classification and diagnosis of urticaria","volume":"64","author":"Zuberbier","year":"2009","journal-title":"Allergy"},{"key":"10.1038\/jid.2014.306_bb0105","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1398-9995.2009.02178.x","article-title":"EAACI\/GA2LEN\/EDF\/WAO guideline: management of urticaria","volume":"64","author":"Zuberbier","year":"2009","journal-title":"Allergy"}],"updated-by":[{"DOI":"10.1038\/jid.2014.512","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000}}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15370652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15370652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T17:47:37Z","timestamp":1743961657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X15370652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0022202X15370652"],"URL":"https:\/\/doi.org\/10.1038\/jid.2014.306","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718498824.793514417","asserted-by":"object"}]},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic\/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/jid.2014.306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Society for Investigative Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}